Quarterly report pursuant to Section 13 or 15(d)

INVESTMENT (Details Narrative)

v3.21.2
INVESTMENT (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Mar. 12, 2021
Jun. 30, 2021
Jun. 30, 2021
Related Party Transaction [Line Items]      
Aggregate investment   $ 6,000,000 $ 6,000,000
Equity investment   5,000,000 5,000,000
Convertible note investment   1,000,000 1,000,000
ILiAD [Member]      
Related Party Transaction [Line Items]      
Aggregate investment   6,000,000 6,000,000
Equity investment   5,000,000 5,000,000
Equity investment - net loss   $ 231,000 $ 446,000
ILiAD [Member] | Class C units [Member]      
Related Party Transaction [Line Items]      
Ownership percentage - non fully diluted   9.50% 9.50%
Ownership percentage fully diluted   7.40% 7.40%
ILiad Biotechnologies LLC [Member]      
Related Party Transaction [Line Items]      
Additional convertible note investment $ 1,000,000    
Maximum convertible debt offering $ 23,500,000    
Interest rate 6.00%    
Notes conversion, description The Notes are required to be converted into a Qualified Financing (minimum financing of $15 million) at the lesser of (i) 80% of the price paid per unit in such offering or (ii) a price based on an enterprise value of $176,000,000. In addition, the Notes shall convert in the event of a merger at the lower of an enterprise value of $176,000,000 or the stated valuation of ILiAD in the merger transaction.